510(k) K233453
K233453 is an FDA 510(k) premarket notification submitted by Life Technologies Corporation for the device "Applied Biosystems TaqPath COVID-19 Diagnostic PCR Kit". The FDA issued a decision of Substantially Equivalent on July 10, 2024. The device falls under product code QQX (Respiratory Specimen Nucleic Acid Sars-Cov-2 Test), a Class II device regulated under 21 CFR 866.3981. Life Technologies Corporation has at least 6 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- July 10, 2024
- Date Received
- October 20, 2023
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
- Device Class
- Class II
- Regulation Number
- 866.3981
- Review Panel
- MI
- Submission Type
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.